Psoriasis

Anti-interleukin 23 inhibitors showed the best short-term safety rates for the treatment of moderate to severe psoriasis, while risankizumab was best in the long term, according to a network meta-analysis.

Complete or near complete skin clearance was reported in an extension study in the majority of patients with psoriasis who received bimekizumab, according to a press release.

Overall psoriasis severity and scalp psoriasis, as well as itch and quality of life, were improved in patients who used apremilast, according to a phase 3 study.

Analgesic opioid use was higher among individuals with psoriasis and those with concomitant psoriasis and psoriatic arthritis compared with the general population, according to findings from a cross-sectional study conducted in Denmark.

The use of biological disease-modifying antirheumatic drugs in patients with psoriasis reduces the risk for psoriatic arthritis, according to data published in the Annals of the Rheumatic Diseases.

Patients with psoriasis initially treated with infliximab or adalimumab had an increased risk for serious infection; however, those treated with IL-12/23, IL-17 or IL-23 inhibitors had a lower infection risk, according to a study.

Patients with psoriasis in the United States may have double the risk of mortality than those who do not have the disease, according to a study.

Patient-completed psoriasis questionnaires showed response agreement over time, while atopic dermatitis questionnaires had inconsistent responses, according to a study.

Psoriasis, affecting 3% of the U.S. adult population, remains one of the most common immune-mediated diseases, according to a study.

Pregnancy can cause myriad changes in a woman’s body. For those with psoriasis or psoriatic disease, the good news is that their condition often clears during pregnancy.